IBT
CBAY icon

International Biotechnology Trust’s Cymabay Therapeutics CBAY Stock Holding History

International Biotechnology Trust’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-145,000
Closed -$1.23M – 53
2018
Q3 		$1.23M Hold
145,000
– – 0.59% 40
2018
Q2 		$1.95M Hold
145,000
– – 0.75% 37
2018
Q1 		$1.88M Hold
145,000
– – 0.74% 33
2017
Q4 		$1.33M Buy
+145,000
New +$1.24M 0.47% 46

Other funds holding CBAY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Eagle Asset Management
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Carillon Tower Advisers
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

International Biotechnology Trust's CBAY Position: Q4 2018 in Review

International Biotechnology Trust sold out of Cymabay Therapeutics (CBAY) in Q4 2018, closing a stake of 145,000 shares — an estimated $1.23M sold.

International Biotechnology Trust first reported a position in CBAY in Q4 2017 and held it in 4 quarters. The position peaked at $1.95M in Q2 2018. 131 funds tracked by Wall St. Rank hold CBAY as of Q4 2018.

  • International Biotechnology Trust reported no remaining Cymabay Therapeutics position as of Q4 2018 after selling out during the quarter.
  • International Biotechnology Trust sold 145,000 Cymabay Therapeutics shares in Q4 2018, an estimated $1.23M.
  • International Biotechnology Trust first reported a position in Cymabay Therapeutics in Q4 2017 and held it in 4 quarters.
  • International Biotechnology Trust's Cymabay Therapeutics position peaked at $1.95M in Q2 2018.
  • 131 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2018.

Based on International Biotechnology Trust's 13F filing for Q4 2018, filed 14 Feb 2019.